Program
Donepezil
Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.
Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.
Drug pageDonepezil: every studyMany companies study it; this page follows only the 79 they lead. All 184 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 391 open or running | phase 4since Sep 12, 2005 | Nov 9, 2004 | May 6, 2030phase 1 · NCT07768592 |
| Pfizerits history only | 70 open or running | phase 4since Sep 9, 2005 | Sep 8, 2005 | none ahead |
| Coriumits history only | 60 open or running | phase 1since Nov 13, 2016 | Nov 13, 2016 | none ahead |
| Merckits history only | 50 open or running | phase 2since Feb 14, 2014 | Oct 21, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 3, 2012 | Jan 3, 2012 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Dec 14, 2010 | Dec 14, 2010 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jul 9, 2008 | Jul 9, 2008 | none ahead |
| Icure Pharmaceuticalits history only | 30 open or running | phase 3since Jun 22, 2017 | May 15, 2013 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jan 11, 2011 | Jan 11, 2011 | none ahead |
| AbbVieits history only | 10 open or running | phase 2since Aug 27, 2015 | Aug 27, 2015 | none ahead |
| Dongkook Pharmaceuticalits history only | 10 open or running | phase 1since Feb 18, 2016 | Feb 18, 2016 | none ahead |
| Teikoku Pharma USAits history only | 10 open or running | phase 2since Jun 5, 2009 | Jun 5, 2009 | none ahead |
| Theranexusits history only | 10 open or running | phase 1since Oct 2, 2018 | Oct 2, 2018 | none ahead |
Also a collaborator on its studies: PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 29, 2007.
- Aug 27, 2015AbbVie’s first study: phase 2 study in Dementia of Alzheimer's TypeNew to AbbVieAbbVie · NCT02549196 · 28 enrolled · United States
- Jan 18, 2016Phase 4 study in Dementia Associated With Cerebrovascular DiseaseEisai · NCT02660983 · 302 enrolled · Korea, Republic of
- Feb 18, 2016Dongkook Pharmaceutical’s first study: phase 1 study in Alzheimer DiseaseNew to Dongkook PharmaceuticalDongkook Pharmaceutical · NCT02695004 · 44 enrolled · Korea, Republic of
- Nov 13, 2016Corium’s first study: phase 1 study in Alzheimer DiseaseNew to CoriumCorium · NCT02968719 · 107 enrolled · United States
- Jun 22, 2017Phase 3 study in Alzheimer DiseaseIcure Pharmaceutical · NCT03197740 · 399 enrolled · Korea, Republic of
- Aug 21, 2017Phase 1 study in Alzheimer DiseaseCorium · NCT03259958 · 86 enrolled · United States
- Nov 3, 2017Phase 1 study in Skin IrritationCorium · NCT03397862 · 256 enrolled · United States
- Jan 31, 2018Phase 1 study in Alzheimer DiseaseCorium · NCT03432195 · 66 enrolled · United States
- Feb 13, 2018Phase 1 study in Alzheimer DiseaseCorium · NCT03438604 · 24 enrolled · United States
- Oct 2, 2018Theranexus’s first study: phase 1 study in Cognitive DysfunctionNew to TheranexusTheranexus · NCT03698695 · 152 enrolled · France
- Mar 11, 2020Phase 1 study in Alzheimer DiseaseMerck · NCT04308304 · 27 enrolled · United States
- Nov 1, 2020Phase 1 study in Healthy SubjectsCorium · NCT04617782 · 60 enrolled · United States
- Jan 26, 2021Phase 1 study in Alzheimer DiseaseMerck · NCT04730635 · 44 enrolled · United States, Australia
- Aug 12, 2026Phase 1 study in Alzheimer DiseaseEisai · NCT07768592 · 32 planned
Ahead
- May 6, 2030Primary completion: phase 1 study in Alzheimer DiseaseEisai · NCT07768592
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
| Z 338rule | Zeria Pharmaceutical | phase 3 | 12 |
Studies
The newest 60 of 79 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768592Alzheimer Disease | 1 | Not yet recruiting | Eisai | May 6, 2030 | 32 |
| NCT04730635Alzheimer Disease · United States, Australia | 1 | Completed | Merck | Jan 20, 2023 | 44 |
| NCT04617782Healthy Subjects · United States | 1 | Completed | Corium | Apr 5, 2021 | 60 |
| NCT04308304Alzheimer Disease · United States | 1 | Completed | Merck | May 18, 2022 | 27 |
| NCT03698695Cognitive Dysfunction · France | 1 | Completed | Theranexus | Oct 20, 2019 | 152 |
| NCT03438604Alzheimer Disease · United States | 1 | Completed | Corium | Jun 19, 2018 | 24 |
| NCT03432195Alzheimer Disease · United States | 1 | Completed | Corium | Jun 28, 2018 | 66 |
| NCT03397862Skin Irritation · United States | 1 | Completed | Corium | Mar 8, 2018 | 256 |
| NCT03259958Alzheimer Disease · United States | 1 | Completed | Corium | Mar 13, 2018 | 86 |
| NCT03197740Alzheimer Disease · Korea, Republic of | 3 | Completed | Icure Pharmaceutical | Jul 3, 2020 | 399 |
| NCT02968719Alzheimer Disease · United States | 1 | Completed | Corium | Jul 11, 2017 | 107 |
| NCT02695004Alzheimer Disease · Korea, Republic of | 1 | Completed | Dongkook Pharmaceutical | Mar 2017 | 44 |
| NCT02660983Dementia Associated With Cerebrovascular Disease · Korea, Republic of | 4 | Completed | Eisai | Jul 13, 2018 | 302 |
| NCT02549196Dementia of Alzheimer's Type · United States | 2 | Completed | AbbVie | Sep 28, 2017 | 28 |
| NCT02345213Lewy Body Disease · Japan | 4 | Completed | Eisai | May 15, 2017 | 160 |
| NCT02178124Alzheimer Disease · Korea, Republic of | 1 | Completed | Icure Pharmaceutical | Dec 2014 | 24 |
| NCT02097056Alzheimer Disease · Korea, Republic of | 4 | Completed | Eisai | May 2015 | 171 |
| NCT02094053Down Syndrome · Japan | 2 | Completed | Eisai | Sep 16, 2016 | 36 |
| NCT02064920Alzheimer Disease | 2 | Completed | Merck | Jul 13, 2016 | 36 |
| NCT02051335Memory Disorders · United Kingdom | 1 | Completed | AstraZeneca | May 2014 | 27 |
| NCT02055703Healthy Subjects · United States | 1 | Completed | Eisai | Apr 2014 | 195 |
| NCT01923558Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 2010 | 76 |
| NCT01923259Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 2010 | 94 |
| NCT01860625Alzheimer Disease · Korea, Republic of | 1 | Completed | Icure Pharmaceutical | Dec 2013 | 36 |
| NCT01843556Healthy Elderly Male · Japan | 1 | Completed | Eisai | Apr 2013 | 48 |
| NCT01539031Alzheimer Disease · Japan | 3 | Completed | Eisai | Jan 2015 | 351 |
| NCT01506752Healthy Adult · Japan | 1 | Completed | Eisai | Sep 2011 | 20 |
| NCT01506739Healthy Adult · Japan | 1 | Completed | Eisai | May 2011 | 12 |
| NCT01504516Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Nov 2009 | 25 |
| NCT01504503Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Nov 2009 | 26 |
| NCT01485185Neuralgia · United Kingdom | 1 | Completed | GlaxoSmithKline | Jul 3, 2012 | 48 |
| NCT01439243Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Jul 2007 | 26 |
| NCT01439230Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Aug 2007 | 36 |
| NCT01404169Alzheimer Disease · China | 3 | Completed | Eisai | Jul 2014 | 260 |
| NCT01278407Lewy Body Disease · Japan | 3 | Completed | Eisai | Mar 2013 | 142 |
| NCT01276353Alzheimer Disease · Japan | 2 | Completed | Eisai | Apr 2012 | 45 |
| NCT01276080Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Nov 2009 | 36 |
| NCT01276067Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Nov 2009 | 32 |
| NCT01260948Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | May 2006 | 26 |
| NCT01260922Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | May 2006 | 26 |
| NCT01181310Dementia | 1 | Completed | Merck | Oct 2007 | 31 |
| NCT01082965Alzheimer Disease · United States | – | Terminated | Pfizer | Jul 2012 | 18 |
| NCT01063556Kidney Failure, Chronic · Japan | 4 | Completed | Eisai | Mar 2010 | 6 |
| NCT01024660Alzheimer Disease · Canada, Peru, Poland and more | Early 1 | Completed | AstraZeneca | Jan 2011 | 155 |
| NCT00959881Alzheimer Disease · United States | 1 | Completed | Pfizer | Nov 2009 | 47 |
| NCT00916383Irritation/Irritant · United States | 2 | Completed | Teikoku Pharma USA | Jun 2009 | 49 |
| NCT00934375Cognitive Dysfunction · United States | 4 | Completed | Eisai | Sep 2007 | 145 |
| NCT01146509Migraine Disorders · United States | 2 | Completed | Eisai | Apr 2004 | 89 |
| NCT00777608Alzheimer Disease | 1 | Completed | Merck | Oct 2009 | 106 |
| NCT00754052Down Syndrome · United States | 3 | Terminated | Eisai | Nov 2008 | 8 |
| NCT00754013Down Syndrome · United States | 3 | Terminated | Eisai | Oct 2008 | 9 |
| NCT00713765Alzheimer Disease · United Kingdom | 1 | Terminated | AstraZeneca | Dec 2008 | 33 |
| NCT00688376Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eisai | May 26, 2009 | 72 |
| NCT00675025Down Syndrome · United States | 2 | Terminated | Eisai | Nov 13, 2008 | 117 |
| NCT00630851Alzheimer Disease · Sweden | 3 | Completed | Pfizer | 249 | |
| NCT00711204Alzheimer Disease · United States | 4 | Withdrawn | Eisai | Jun 2009 | 0 |
| NCT00598650Lewy Body Disease | 2 | Completed | Eisai | Mar 2011 | 160 |
| NCT00571064Mild to Severe Alzheimer's Disease · United States | 4 | Completed | Eisai | Dec 2008 | 97 |
| NCT00570128Down Syndrome · United States | 2 | Completed | Eisai | Sep 5, 2008 | 129 |
| NCT00566501Alzheimer Disease · United States | 3 | Completed | Eisai | Apr 1, 2010 | 915 |
How it is read
Names in the registry
- “Donepezil”, 26 entries
- “Donepezil Hydrochloride”, 14 entries
- “E2020”, 7 entries
- “Donepezil TDS”, 5 entries
- “Donepezil hydrochloride”, 5 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 38 studies
- Down Syndrome, 5 studies
- Lewy Body Disease, 4 studies
- Cognitive Dysfunction, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.